AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02480127 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PIPELLE Endometrial injury
Description: The endometrial injury which is induced with pipelle.
Study NCT01146106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin Sodium
Description: Pravastatin Sodium Tablets 80 mg
Study NCT01146106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin Sodium
Description: Pravastatin Sodium Tablets 80 mg
Study NCT03823469 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CCTP
Description: Twelve weekly one-on-one 30-minute tele-sessions through video conference. At the first session, subjects identify their vision regarding home cooking and 3-month goals. During each subsequent meeting, subjects will review their progress towards reaching the prior week's culinary goals and identify goals for the coming week, using a self-discovery process. When patients detect a new culinary skill that is necessary for their progress, s/he will either be taught through discussions or referred to active learning from a Culinary Resource Center.
Study NCT03823469 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional counseling
Description: Two 30-minute nutritional counseling sessions
Study NCT00663065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAZ-417
Study NCT02757664 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shock Wave Therapy
Description: Appliance of radial shock waves with the BLT600 equipment (BTL Medical Technologies - Canada), the intensity being 2000 to 3000 pulses, 7 to 10Hz of frequency, and 1,5 a 2,5Bar of intensity per application; Appliance on the first day of treatment (D0), repeated on the second week after the first intervention (2nd week) and four weeks after the first intervention (4th week).
Study NCT02757664 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Eccentric Exercises
Description: 12 weeks, starting on the same day of the first appliance. The patient will practice the exercises standing on tiptoes and will perform exercises of passive ankle extension (dorsiflexion), three series of 15 repetitions, with the knee stretched, and three series of 15 repetitions with the knee flexed by 20 degrees.
Study NCT02757664 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric Exercises
Description: 12 weeks, starting on the same day of the first appliance. The patient will practice the exercises standing on tiptoes and will perform exercises of passive ankle extension (dorsiflexion), three series of 15 repetitions, with the knee stretched, and three series of 15 repetitions with the knee flexed by 20 degrees.
Study NCT02757664 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placing of the apparatus´ therapeutic head with the support that impedes the shock wave propagation directly on the appliance field; Appliance of radial shock waves with the BLT600 equipment (BTL Medical Technologies - Canada), the intensity being 2000 to 3000 pulses, 7 to 10Hz of frequency, and 1,5 a 2,5Bar of intensity per application; Appliance on the first day of treatment (D0), repeated on the second week after the first intervention (2nd week) and four weeks after the first intervention (4th week).
Study NCT02997579 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patellar resurfacing
Description: patellar component insert with cement
Study NCT02949752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole 5 mg every morning will be prescribed for 12 weeks
Study NCT05076539 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Garmin GPS activity tracker
Description: 50 patients will be issued a Garmin GPS-activity tracker where they will be required to wear for 24 hours for 1 week, prior to each timepoint (pre-operatively and 6 months post surgery).
Study NCT03106038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerindocianine for Injection
Description: Procedure: routine minimally invasive pelvic surgery.
Study NCT03445091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SANKOM Patent Socks
Description: Using compression socks to ease symptoms of patients with chronic venous insufficiency
Study NCT02141711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets
Study NCT02141711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-438 Placebo
Description: TAK-438 placebo-matching tablets
Study NCT02097147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone 20 mg
Description: Oral administration, once per day.
Study NCT02097147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg
Description: Oral administration, once per day.
Study NCT02097147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine 20 mg
Description: Oral administration, once per day.
Study NCT02097147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration, once per day.
Study NCT04437355 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Specific provocation test
Description: To compare the results the investigators invite a healthy control group matching in age and gender with the intervention cohort. The control group is informed about the study and asked to participate in the outpatient clinic. In case of informed consent, the participants are invited to the study site. The participants undergo the same provocation test of the ankle, and are asked to complete the specific provocation test. In case of substantial underachievement in the provocation test (\<60% of maximum) an X-Ray of both ankles in a.p. and lateral projection is performed. The aim is to radiologically analyse the ankles, and to rule out any morphological reasons for the above mentioned underperformance.
Study NCT03730337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7475
Description: ONO-7475 specified dose on specified days
Study NCT03730337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7475 + ONO-4538
Description: ONO-7475+ONO-4538 specified dose on specified days
Study NCT02137954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Study NCT02137954 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04015154 — intervention group
Intervention type: DEVICE
Intervention: Femoral Nail PF of the T2 Alpha Femur Antegrade GT/PF Nailing System
Description: The T2 Alpha Femur Antegrade GT / PF Nailing System is intended for temporary stabilization of bone segments or fragments until bone consolidation has been achieved.
Study NCT03298022 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALTB-168
Description: monoclonal antibody
Study NCT01029067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive training
Description: Group (8 sessions) and individualized metacognitive training (9 sessions), delivered by psychologists versus cognitive remediation (8 sessions) delivered by either psychologists or psychology students at an advanced master level
Study NCT01029067 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation
Description: Group (8 sessions) and individualized metacognitive training (9 sessions), delivered by psychologists versus cognitive remediation (8 sessions) delivered by either psychologists or psychology students at an advanced master level
Study NCT03222791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Algorithm-based diet
Description: Personalized nutrition plan based on an algorithm for predicting the personalized glucose response to food. The algorithm's predictions are based on many personal measurements, including blood tests, personal lifestyle and gut bacteria.
Study NCT03222791 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mediterranean-style low-fat diet
Description: The Israeli standard of care dietary guidelines for prediabetes.
Study NCT03692728 — intervention group
Intervention type: OTHER
Intervention: Psychological and Behavioral Problems
Description: Differences in age and sex between the CC and NV groups were compared using the independent samples t test and Chi-square test, respectively. Comparisons of abnormal rates between the CC and NV groups were performed using the Chi-square test. Scores on all subscales recorded for the CC group were compared with those of the NV group and the Chinese urban norm using the independent samples t test and one-sample t test, respectively.
Study NCT02090322 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of bevacizumab intravitreal (Avastin)
Description: The treatment of Retinopathy of prematurity is with bevacizumab intravitreal for resolution of the illness.~When there is a Retinopathy of prematurity type 1, is the indication for the infection
Study NCT02526004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Study NCT02526004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftazidime
Study NCT02526004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin
Study NCT02526004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin
Study NCT02312635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: Half of the participants will be randomly chosen to receive the medication D-cycloserine in addition to the working memory program, while the other group will receive an inactive pill (placebo).
Study NCT02312635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed Working Memory Training
Description: Both arms of the study will receive Cogmed working memory training for 6 weeks, M-F.
Study NCT02312635 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cogmed Working Memory Training
Description: Both arms of the study will receive Cogmed working memory training for 6 weeks, M-F.
Study NCT04163250 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary determination of TIMP-2/ IGFBP7
Description: Urinary determination of TIMP2-IGFBP7 in the an urine sample obtained within 12 hours prior to contrast administration. A single determination will be made, which will be sent to the laboratory. The doctor who treats the patient will not know the result of the test, and the treatment will not be influenced by the result.~According to the manufacturer, 10 ml of fresh urine should be collected in a sterile container and the laboratory should centrifuge them within the time of collection.~The result is reported as a single value calculated as the concentration of TIMP-2 (ng / mL) multiplied by the concentration of IGFBP7 (ng / mL) divided by 1000. The result is reported without units.
Study NCT02966691 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VisioCyt® diagnostic test
Description: The cytology slides obtained from the current practice will be compared to the slides obtained with the Visiocyt protocol, for each arm.
Study NCT01962233 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: Procedure: On the basis of conventional therapy, at the same time, selected patients were given by intravenous infusion of umbilical cord blood stem cells 100-800 million. All patients before treatment, after treatment for 15days, 90days and 180 days were evaluated respectively the curative effect.~Intravenous infusion of umbilical cord derived mesenchymal stem cells
Study NCT02035995 — intervention group
Intervention type: OTHER
Intervention: Pregnant volunteers with GDM
Study NCT00470600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caldolor
Description: 800 milligrams intravenous
Study NCT00470600 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo comparator
Study NCT03461757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant
Description: 75 mg ODT QD
Study NCT03461757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ODT to match rimegepant dose QD
Study NCT02126709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repigel
Description: Repigel will be used as the intervention in the treatment group
Study NCT01550562 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Boston Scientific Precision Plus spinal cord stimulation therapy
Description: Epidural spinal cord stimulation (SCS) using the Boston Scientific Precision Plus SCS system
Study NCT01550562 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boston Scientific Precision Plus spinal cord stimulation therapy
Description: Epidural spinal cord stimulation (SCS) using the Boston Scientific Precision Plus SCS system
Study NCT01550562 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific Precision Plus spinal cord stimulation therapy
Description: Epidural spinal cord stimulation (SCS) using the Boston Scientific Precision Plus SCS system
Study NCT04405011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 24-week Entecavir
Description: Entecavir 0.5mg for 24 weeks will be delivered
Study NCT04405011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 12-week Entecavir
Description: Entecavir for 12 weeks will be delivered and serve as the active comparator arm
Study NCT03225300 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Simultaneous integrated boost
Description: Simultaneous integrated boost (SIB), a field-in-field escalation technique, has been introduced to deliver higher radiation dose to the certain part of target with the same fractionation scheme.
Study NCT03467646 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve Gastrectomy
Description: The patients undergo a Sleeve Gastrectomy as bariatric procedure
Study NCT03467646 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y gastric bypass
Description: The patients undergo a Roux-en-Y gastric bypass as bariatric procedure
Study NCT03467646 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One-Anastomosis Gastric Bypass
Description: The patients undergo a One-Anastomosis Gastric Bypass as bariatric procedure
Study NCT04223934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: optima4BP
Description: optima4BP establishes a no gaps computational framework in determining the most effective treatment change that can optimize a patient's HTN management towards BP Target. All possible drug combination options available through the 16 anti-HTN drug classes and subclasses are quantitatively evaluated in the context of 5 actions: add a drug, remove a drug, replace a drug, increase a drug dose, and decrease a drug dose. The pharmacological intervention efficacy ranking is computed and the highest ranked treatment recommendation is selected for consideration by the treating physician.
Study NCT00303251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Study NCT02791490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin IR
Description: All participants will take Met-IR as background medication. Initially, they will take 1 x 500 mg tablet Met-IR b.i.d. (1000 mg/day). After randomization, all participants will be titrated to 2 x 500 mg tablets of Met-IR b.i.d. (2000 mg/day).
Study NCT02140294 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polymeric nutritional supplements
Study NCT04034862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment simplification (dolutegravir lamivudine)
Description: Switch from 3 drug regimen (DTG/ABC/3TC) to 2 drug regimen
Study NCT02140294 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Nutrional Treatment
Study NCT03953404 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SPLA2-IIA
Description: bedside blood test
Study NCT02032173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5mg
Description: Intravitreal injection with standard dose of 0.5 mg/0.05mL Pro re nata (PRN)
Study NCT02355561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment A)
Description: Participants will receive a single oral 25 mg formulation 1 of JNJ-54861911 tablet as Treatment A under fasted conditions in one of the treatment periods.
Study NCT02355561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment B)
Description: Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment B under fasted conditions in one of the treatment periods.
Study NCT02355561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment C)
Description: Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment C under fed conditions in one of the treatment periods.
Study NCT03318146 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug delivery system
Description: The EXP-LP sustained released formula inserted into a small punctual plug. The plug is designed to release the drug over a period of up to 6 months in a slow release profile.
Study NCT03318146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XALATAN®
Description: one drop in the affected eye(s) once daily in the evening
Study NCT04513431 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CEA-CAR T
Description: T cells modified with CEA targeted chimeric antigen receptor.
Study NCT00106171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy (HAART)
Description: Regimens will be assigned by investigators
Study NCT00500526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Singing practice
Study NCT00500526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Singing classes
Study NCT00500526 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hand craft classes
Study NCT02468791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Study NCT02468791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT02573155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 1, AZD8871 50 μg (Part 1)
Description: 50 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
Study NCT02573155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 2, AZD8871 100 μg (Part 1)
Description: 100 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
Study NCT02573155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 3, AZD8871 300 μg (Part 1)
Description: 300 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
Study NCT02573155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 4, AZD8871 600 µg (Part 1)
Description: 600 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
Study NCT02573155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 5, AZD8871 1200 µg (Part 1)
Description: 1200 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
Study NCT02573155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 6, AZD8871 1800 μg (Part 1)
Description: 1800 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
Study NCT02573155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, AZD8871 placebo (Part 1)
Description: AZD8871 placebo on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
Study NCT02573155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A, AZD8871 dose A (Part 2)
Description: AZD8871 dose A once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
Study NCT02573155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B, AZD8871 dose B (Part 2)
Description: AZD8871 dose B once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler(Genuair®)
Study NCT02573155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C, Indacaterol 150 μg (Part 2)
Description: 150 μg of Indacaterol once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (Onbrez Breezhaler®) as 1 hard capsule
Study NCT02573155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D, Tiotropium 18 μg (Part 2)
Description: 18 μg of Tiotropium once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (HandiHaler®) as 1 hard capsule
Study NCT02285725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microdrilling Surgery
Description: All patients will undergo an arthroscopic surgical procedure in which small holes are drilled throughout the areas of damaged cartilage (standard of care)
Study NCT02285725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injections of BMAC + PRP + HA
Description: All patients will receive up to 12 intra-articular knee injections of BMAC (derived from iliac crest), PRP (derived from peripheral blood) and HA
Study NCT01665144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312
Description: 0.25, 0.5, 1, and 2 mg film-coated tablets
Study NCT01665144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablets